REGENXBIO Inc.
REGENXBIO Inc.
ROCKVILLE, MD
Loading...
Price History
Market Data
| Market Cap | 630,000.00 |
| P/E Ratio | - |
| P/B Ratio | 0.01 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 3.41 |
| Current Ratio | 2.38 |
| Currency | USD |
Key Financial Metrics
170.44M
Revenue
-193.88M
Net Income
-
EPS (Diluted)
-110.90M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-94.6%
Net Profit Margin
-113.8%
EBITDA
-133.77M
Returns & Efficiency
Return on Assets (ROA)
-42.8%
Return on Equity (ROE)
-188.7%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
453.03M
Total Debt
-
Debt to Equity
3.41x
Current Ratio
2.38
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | ROCKVILLE, MD |
| Fiscal Year | 2025 |
Peers
AMGEN INC
AMGN
178.46B
P/E: --
GILEAD SCIENCES INC
GILD
162.80B
P/E: --
162.80B
P/E: --
BIOGEN IDEC INC.
BIIB
28.41B
P/E: --
BIOGEN INC.
BIIB
28.41B
P/E: --
MODERNA, INC.
MRNA
21.50B
P/E: --
Moderna, Inc.
MRNA
21.50B
P/E: --
19.11B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$630.00K
P/E Ratio (TTM)-
Price to Book0.01
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-94.6%
Net Margin-113.8%
ROE-188.7%
ROA-42.8%
Leverage & Liquidity
Debt to Equity3.41
Current Ratio2.38
Total Debt-
Total Assets$453.03M
Stockholders' Equity$102.73M
Income Statement (FY 2025)
Revenue$170.44M
Gross Profit-
Operating Income$-161.20M
Net Income$-193.88M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-110.90M
Cash & Equivalents$34.47M
Revenue Growth104.5%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 9804 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850 |
| Phone | N/A |
| Incorporated | , US |
| EIN | 471851754 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 60,000.00 |
| Stockholders' Equity | $102.73M |
| Cash & Equivalents | $34.47M |
Recent Filings
View All
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-14
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-14
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-14
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-10
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-05
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-05
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-02-12
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-10
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-07
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-12
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-08
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-03-13
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-11-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-08-01
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | REGENXBIO Inc. |
| Ticker | RGNX |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | ROCKVILLE, MD |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 630,000.00 |
| Revenue | 170.44M |
| Net Income | -193.88M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | -113.8% |
| ROE | -188.7% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...